Reported a net loss of $1.0 million for the three months ended March 31, 2026, compared to a $1.07 million loss in the same period of 2025. Cash and cash equivalents totaled $0.35 million as of March 31, 2026, down from $1.385 million at year-end 2025. Operating expenses for the quarter were $1.01 million, primarily driven by research and development costs for the ALN1003 obesity program. The company is currently in non-compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. Management has issued a going concern warning, noting that existing cash is only sufficient to fund operations into the second quarter of 2026.